Categories: News

electroCore to Announce First Quarter Financial Results on Wednesday, May 3

ROCKAWAY, N.J., April 19, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2023, after the close of the market on Wednesday, May 3, 2023. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.

Wednesday, May 3, 2023, 4:30 PM EDT
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13738144
Webcast: electroCore Earnings Webcast

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Contact:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

26 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

27 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

30 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

30 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

30 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

30 minutes ago